Dyne Therapeutics, Inc. (DYN)
| Market Cap | 2.07B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -412.89M |
| Shares Out | 142.26M |
| EPS (ttm) | -3.87 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,009,487 |
| Open | 14.07 |
| Previous Close | 13.95 |
| Day's Range | 13.89 - 14.60 |
| 52-Week Range | 6.36 - 35.90 |
| Beta | 1.08 |
| Analysts | Strong Buy |
| Price Target | 34.93 (+139.9%) |
| Earnings Date | Nov 11, 2025 |
About DYN
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and i... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for DYN stock is "Strong Buy." The 12-month stock price target is $34.93, which is an increase of 139.90% from the latest price.
News
Dyne: Accelerated Approval Established Endpoint Sets Stage For DM1 Data In Mid-2026
Dyne Therapeutics received positive FDA feedback enabling a registrational cohort for z-basivarsen in DM1, with Accelerated Approval possible using vHOT as intermediate efficacy endpoint. DYN expects ...
Dyne Therapeutics Announces Additional One-Year Clinical Data Demonstrating Functional Improvement from Phase 1/2 ACHIEVE Trial of Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)
- Robust improvement demonstrated across diverse set of clinical measures - - Patient-reported outcomes support clinical meaningfulness of improvements in function and strength - - Meaningful improvem...
Dyne Therapeutics Appoints Brian Posner to its Board of Directors
WALTHAM, Mass., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically drive...
Dyne Therapeutics Receives Orphan Drug Designation in Japan for DYNE-251 in Duchenne Muscular Dystrophy
- Data from ongoing DELIVER trial demonstrated sustained functional improvement through 18 months; results from Registrational Expansion Cohort expected late 2025 -
Dyne Therapeutics, Inc. (DYN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
Dyne Therapeutics, Inc. (NASDAQ:DYN) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 9:15 AM EDT Company Participants John Cox - CEO, President & Director Erick Lucera - CFO...
Dyne Therapeutics to Present at Upcoming Investor Conferences
WALTHAM, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically drive...
Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD)
- Data from the DELIVER registrational expansion cohort is expected in late 2025, with a potential BLA submission for U.S. accelerated approval anticipated in early 2026 -
These Analysts Lower Their Forecasts On Dyne Therapeutics Following Q2 Loss
Dyne Therapeutics Inc DYN reported a loss for the second quarter on Monday.
Dyne Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights
- Expected cash runway extended into Q3 2027, beyond multiple potential inflection points including Dyne's first planned commercial launch in early 2027 -
Satellos Appoints Dr. Wildon Farwell as Chief Medical Officer
TORONTO--(BUSINESS WIRE)--Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a biotech company developing new small molecule therapeutic approaches to improve the treatm...
Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
WALTHAM, Mass., July 02, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven ...
Tesla, Progress Software, Dyne Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling around 0.1% on Tuesday.
Dyne Therapeutics Announces Pricing of $200.0 Million Public Offering of Common Stock
WALTHAM, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven...
Dyne Therapeutics Announces Proposed Public Offering of Common Stock
WALTHAM, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven...
Dyne Therapeutics Secures Up to $275 Million in Debt Financing from Hercules Capital
- $100 million funded upfront; additional $175 million tied to milestones provides strategic flexibility through key inflection points -
Dyne Therapeutics Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - DYN
LOS ANGELES , June 24, 2025 /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of Dyne Therapeutics ("Dyne" or "the Company") (NASDAQ: DYN) for violatio...
Dyne Therapeutics - Emergence As A Superior DM1 / DMD Player Warrants Rating Upgrade
Upgrading Dyne Therapeutics to 'Buy' due to promising late-stage DM1 and DMD drug candidates and significant unmet need in both indications. Recent management changes and a more measured clinical appr...
Dyne Therapeutics Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – DYN
LOS ANGELES--(BUSINESS WIRE)---- $DYN--Dyne Therapeutics Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – DYN.
Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-101 and Updated Plan for Accelerated Approval in DM1 Following Type C Meeting
- Based on Type C meeting and new data, Dyne submitted revised ACHIEVE trial protocol to FDA elevating vHOT to primary endpoint for U.S. Accelerated Approval - - New positive clinical data from Phase ...
Dyne Therapeutics to Host Investor Conference Call and Webcast to Provide Update on DYNE-101 for Myotonic Dystrophy Type 1, Tomorrow Tuesday, June 17 at 8:00 a.m. ET
WALTHAM, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage neuromuscular disease company focused on advancing innovative life-transforming therapeutics ...
Dyne Therapeutics to Present New Preclinical Data in Facioscapulohumeral Muscular Dystrophy at the FSHD Society International Research Congress
- DYNE-302 Demonstrated Functional Improvement in an FSHD Preclinical Model - WALTHAM, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused...
Dyne Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
- FDA (CDER) Type C meeting held in May 2025 for DYNE-101 in DM1 and Dyne plans to provide a regulatory update following receipt of meeting minutes -
Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-251 in Duchenne Muscular Dystrophy
- Recently presented data demonstrated sustained functional improvement with DYNE-251 treatment through 18 months - - Data from the fully enrolled DELIVER registrational expansion cohort is planned fo...
Dyne Therapeutics Announces Chief Business Officer and Chief Scientific Officer Appointments
- Vikram Ranade, PhD, appointed as chief business officer - - Ranjan Batra, PhD, appointed as chief scientific officer - - Oxana Beskrovnaya, PhD, transitioning to chief innovation officer - WALTHAM, ...
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., April 14, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with geneticall...